4me, Inc.
The Acquisition Broadens the Reach of 4me® and Expands Its Capabilities by Integrating Real-Time Technology Service Status Updates for IT Teams, Service Providers and Customers
SANTA BARBARA, CA / ACCESSWIRE / April 2, 2024 / 4me®, the SaaS-based Service Management software platform for the modern enterprise, has completed the acquisition of StatusCast™. StatusCast is a cloud-based provider of incident management products. The acquisition strengthens 4me's position in the ITSM market and represents another advancement in its efforts to assist companies in transforming their businesses with the most advanced and complete service management platform in the industry.
"Our mission is to make IT teams more productive while we directly help our partners and customers deliver great customer experiences. Our transformation of traditional service management is built on an advanced technology platform," said Kevin McGibben, CEO of 4me. "Integrating StatusCast's leading capabilities for incident management and status updates with 4me's core IT Service Management capabilities strengthens the IT operational power of our platform."
"We are incredibly excited to join the fantastic team at 4me," said Eric Warth, VP of Operations at StatusCast. "4me's cutting-edge ITSM solution, with its emphasis on a comprehensive, service-centric, multi-tenant architecture, perfectly complements our mission to unify and automate status and incident communications. This acquisition is in line with our vision of transparently communicating with stakeholders relevant information efficiently so that teams can focus more on the incident than managing communications."
Companies like 8x8 use StatusCast's features to ensure seamless productivity and enhanced communication with their customers. These features include public and private status pages, configurable notifications, and subscriptions for the public, partners or customers. They can provide information about service availability, current incidents or scheduled downtime.
4me will now be able to deliver the following benefits with the addition of StatusCast:
- Real-time service status notifications. Status page updates and notifications will enable IT organizations to provide public status pages, internal and customer status pages reflecting availability and status, including degradation and downtimes of critical services, technologies, and applications.
- Visuals of the status of the IT service catalog, which will integrate with 4me incident management, automatically allowing for faster mean time to resolution (MTTR) in outages and service degradations.
- MSPs, Network Operations Centers, support and service desk teams can use StatusCast incident management to add a layer of automation and end-to-end capability for incident management and service level agreement (SLAs) management for their clients.
To learn more, visit https://www.4me.com/it-service-management.
About 4me
4me is transforming service management for the modern enterprise. 4me's AI-forward, service-oriented, multi-tenant SaaS platform seamlessly connects teams to optimize IT service management. 4me's ability to automate cross-functional workflows makes frictionless service delivery possible, significantly improving business outcomes. The 4me platform's ease of use and deployment makes it the most advanced ITSM platform available today. Hundreds of organizations around the world look to 4me to elevate their Enterprise Service Management. To learn more, visit www.4me.com.
About StatusCast
Founded in 2013, StatusCast's mission is to help IT departments and SaaS companies keep their employees and customers better informed when applications or IT infrastructure goes down. StatusCast is a communication platform for the enhanced and timely distribution of critical information related to outages and maintenance, enabling organizations to be as effective as possible when problems occur. StatusCast's solutions are used by many of the world's leading Fortune 500 companies and SaaS brands.
Contact Information
Carlyn Manly
Marketing
carlyn.manly@4me.com
SOURCE: 4me
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom